Background

The *Florida Morbidity Statistics Report* is the official record of the occurrence of reportable diseases in Florida and this edition marks the 59th publication since 1945. While numerous reports describing the disease burden are produced throughout the year, this report is noteworthy as the data contained here are final. The mission of the Florida Department of Health is to protect, promote, and improve the health of all people in Florida through integrated state, county, and community efforts. Per section 381.003, Florida Statutes "The Department shall conduct a communicable disease prevention and control program as part of fulfilling its public health mission." This report directly supports the mission of the Department by identifying patterns and trends in the incidence of disease that are used as the scientific basis for development of disease control and prevention strategies and policies.

Disease control and prevention are core functions of any public health agency. Protection of the public's health from existing, emerging, and re-emerging diseases requires diligence in all aspects of public health. Public health partners identifying and characterizing emerging trends in disease are the physicians, nurses, laboratorians, hospital infection preventionists, and other health care professionals who participate in reportable disease surveillance. Without their participation, the ability to recognize and intervene in emerging public health issues would be much more limited.

Acknowledgements

The Bureau of Epidemiology thanks all program areas within the Florida Department of Health that contributed to this report including the sections of HIV/AIDS, Immunization, Sexually Transmitted Diseases (STDs) and Viral Hepatitis, and Tuberculosis Control. Finally, many thanks are extended to the local health office staff and other public health professionals who are involved in reportable disease surveillance, either through disease control activities, case investigations, data collection, laboratory testing, or other essential functions.

Purpose

The Florida Morbidity Statistics Report is compiled in a single reference document to:

- Summarize annual morbidity from reportable communicable diseases and diseases of environmental origin in Florida.
- Describe patterns of disease that can be assessed over time, compared with trends from other states, and act as an aid in directing future disease prevention and control efforts.
- Provide a resource to medical and public health authorities at county, state, and national levels.

Data Sources

Data presented in this report are based on reportable disease information received by county and state health department staff from physicians, hospitals, and laboratories throughout the state obtained through passive and active surveillance. Reporting of suspected and confirmed reportable diseases and conditions in the state of Florida is mandated under section 381.0031, Florida Statutes and Florida Administrative Code Chapter 64D-3. People in charge of laboratories, hospitals, medical facilities, or other facilities providing health services (which can include schools, nursing homes, and state institutions) are required to report certain diseases and conditions and the associated laboratory test results as listed in the Table of Notifiable Diseases or Conditions to be Reported, Florida Administrative Code Chapter 64D-3. Reporting of test results by a laboratory does not nullify a practitioner's obligation to report the disease or condition. These data are the basis for providing useful information on reportable diseases and conditions in Florida to health care workers and policymakers, and would not be possible without the cooperation of the extensive network involving both private and public sector participants.

Data are collected by multiple means:

- Passive surveillance relies on physicians, laboratories, and other health care providers to report
 diseases to the Florida Department of Health confidentially in one of three forms: electronically, by
 telephone, or by facsimile. Increasingly, information about cases of reportable diseases and
 conditions is passed from providers, especially laboratories, to the Department as electronic
 records. This occurs automatically, without the involvement of a person after the electronic
 transmission process has been established between the Department and the reporting partner.
- Active surveillance entails Department staff regularly contacting hospitals, laboratories, and physicians in an effort to identify all cases of a given disease or condition.

References

The following references were used in many of the disease-specific chapters within Section 2: Data Summaries for Selected Reportable Diseases/Conditions of Frequent Occurrence.

Centers for Disease Control and Prevention. CDC A-Z Index. Available at www.cdc.gov/az/a.html.

- Centers for Disease Control and Prevention. 2015. *Epidemiology and Prevention of Vaccine-Preventable Diseases*, 13th ed. Washington, D.C.: Public Health Foundation. Available at www.cdc.gov/vaccines/pubs/pinkbook/index.html.
- Centers for Disease Control and Prevention. 2012. *Manual for the Surveillance of Vaccine- Preventable Diseases*, 5th ed. Available at www.cdc.gov/vaccines/pubs/surv-manual/index.html.
- Centers for Disease Control and Prevention. 2016. *CDC Health Information for International Travel 2016*. New York: Oxford University Press. Available at wwwnc.cdc.gov/travel/page/yellowbookhome.
- Centers for Disease Control and Prevention. 2014. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months United States, 2013. *Morbidity and Mortality Weekly Report*, 63(34);741-748. Available at www.cdc.gov/mmwr/preview/mmwrhtml/mm6334a1.htm?s cid=mm6334a1 w.
- Heymann DL (ed). 2015. *Control of Communicable Diseases Manual*. 20th ed. Washington, D.C.: American Public Health Association Press.

Interpreting the Data

Information in this report should be interpreted in light of the limitations below.

1. Under-reporting

The data presented in this report are primarily based on passive reporting by health care providers and laboratories across Florida. Case reporting is most often dependent upon a person becoming ill, seeking medical attention, the health care provider ordering laboratory testing, and finally the health care provider or laboratory reporting the case. Frequently, not all steps in this process occur, so the number of reported cases represents a fraction of the true number of cases of reportable illnesses occurring in Florida each year. Evaluations of infectious disease reporting systems have indicated that the completeness of reporting varies by disease. The less common but more severe reportable diseases such as bacterial meningitis, diphtheria, polio, botulism, anthrax, tuberculosis, and congenital syphilis are more completely reported than the more common diseases with less severe symptoms such as hepatitis A or campylobacteriosis. Variation in identified disease incidence at the local level probably reflects, to varying degrees, both differences in the true incidence of disease and differences in the vigor with which surveillance is performed.

Reliability of Rates

All incidence rates in this report are expressed as the number of reported cases of a disease or condition per 100,000 population unless otherwise specified. All population estimates are from the Community Health Assessment Resource Tool Set (CHARTS), a Florida Department of Health web-based data guery system with community tools, health indicators, and data gueries for public consumption (www.floridacharts.com/charts/default.aspx). Population estimates within CHARTS are provided by the Florida Department of Health, Division of Public Health Statistics and Performance Management, in consultation with the Florida Legislature's Office of Economic and Demographic Research. Estimates in CHARTS are updated at least once per year, and population data were extracted from CHARTS for this report on August 7, 2015, after the annual update in CHARTS. Note that previous editions of this report may show somewhat different populations for a given year than the ones shown here, as these estimates are revised periodically. This is especially true given the recent 2010 census.

Animal rabies is not expressed as a rate; it is only expressed as the number of cases because no reliable denominators exist for animal populations.

Rates for diseases with only a few cases reported per year can be unstable and should be interpreted with caution. The observation of zero events is especially difficult to interpret. Rates were not generally calculated in this report when there were less than 20 cases, except as part of graphs and maps. In some cases, even though maps and graphs (e.g., by year, gender, race) may have small individual counts, rates were calculated. These maps include footnotes as a reminder that rates based on less than 20 cases are not reliable.

3. Determining How Cases are Counted: Reporting Period and Cases Included There are important differences by disease that determine how cases are "counted" and summarized in this report. The date of illness onset or the date of diagnosis may not be available for all cases. Cases reported early in 2014 may have actually had onset or been diagnosed in 2013; rarely, cases reported in 2014 may have onset or diagnosis dates prior to 2013. Additionally, cases with illness onset or diagnosis late in 2014 may not have been reported to public health by the end of the 2014 report year, and thus would not be included in this report for most diseases. Information by disease is listed below.

AIDS and HIV Infection

Year: Data are aggregated by calendar year.

Cases included: HIV infection cases are assigned to a report year based on the date of the first confirmed HIV test. AIDS cases are assigned to a report year based on the date of an AIDS defined opportunistic infection and/or a CD4 count below 200 on a person with HIV infection. The 2014 AIDS and HIV infection dataset was frozen on December 31, 2015. Changes occurring after that point that affect the number of cases in 2014 or earlier will be updated in the following year's dataset.

Please note that prior to 2014, HIV infection and AIDS cases were assigned to a report year based on the date the case was entered into the surveillance system.

Sexually Transmitted Diseases (STDs)

Year:

Data are aggregated by the standard reporting year as outlined by the Centers for Disease Control and Prevention (CDC), where every year has at least 52 reporting weeks and some years have 53 (there were 53 weeks in 2014). This is referred to as the Morbidity and Mortality Weekly Report (MMWR) year.

Cases included: Cases are assigned to a report year based on the date the case was entered into the surveillance system. Occasionally, STD reports are received after the end of the reporting year that should have been included based on the laboratory result date. For these cases, the laboratory result date is used for the report date.

Tuberculosis

Year: Data are aggregated by MMWR year (see STD report year above for explanation

of MMWR year).

Cases included: Cases are assigned to a report year based on the date when the suspected

diagnosis is confirmed by clinical, radiographic, and laboratory testing (often

referred to as "date counted").

All Other Diseases

Year: Data are aggregated by MMWR year (see STD report year above for explanation

of MMWR year).

Cases included: Cases are assigned to a report year based on the date the case was determined

to have enough information to be submitted by local health office epidemiology

staff to the Bureau of Epidemiology for state-level review.

Data in this report are consistent with national surveillance data published weekly by CDC in the MMWR. Additionally, disease-specific reports describing data by other dates, such as disease onset and diagnosis dates, may also be published and available on the Florida Department of Health website.

4. Case Definition

Cases of most diseases are classified as confirmed, probable, or suspect at the state level using a published set of surveillance case definitions consistent with national case definitions where appropriate (Surveillance Case Definitions for Selected Reportable Diseases in Florida, available at www.FloridaHealth.gov/DiseaseCaseDefinitions). Case classifications are reviewed at the state level for most diseases. Following CDC Morbidity and Mortality Weekly Report (MMWR) print criteria (available at www.cdc.gov/nndss/script/downloads.aspx), only confirmed and probable cases have been included (i.e., suspect cases are excluded) in this report unless otherwise specified.

Changes to case definitions can affect the number of cases reported, which can impact calculated incidence rates, but ultimately case definition changes do not change the true incidence of a disease. Each year case definitions are evaluated for necessary revisions. A number of changes were made to reportable disease case definitions in 2014 as a result of position statements approved by the Council of State and Territorial Epidemiologists (CSTE) in 2013.

Summary of case definition changes effective January 2014:

- a. Acute arboviral disease (neuroinvasive and non-neuroinvasive): revised the clinical criteria (removed fever and added chills) and refined laboratory criteria.
- b. Malaria: expanded the confirmed case classification to include detection of unspeciated malaria parasite by microscopy.
- c. Pertussis: added apnea to clinical criteria for infants aged <1 year and expanded probable case classification to include infants with acute cough of any duration and one other symptom who have a positive polymerase chain reaction (PCR) test or an epidemiological link to a confirmed case or a PCR-positive probable infant case.</p>
- d. Trichinellosis: added a probable case classification for people with clinically compatible illness and appropriate exposure and a suspect case classification for people with clinically compatible illness with a positive serologic test and appropriate exposure (note that suspect cases are not included in this report).

- e. Saxitoxin: added a probable case classification for people with clinically compatible illness who have appropriate exposure or are epidemiologically linked to confirmed cases (previously captured in the suspect case classification) and revised the suspect case classification to include people with clinically compatible illness whose exposure history is unknown.
- f. Shiga toxin-producing *Escherichia coli*: expanded the epidemiological linkage criteria for the probable case classification.

5. Assigning Cases to Counties

Cases are assigned to Florida counties following national guidance and based on the county of residence at the time of the disease identification, regardless of where they became ill or were hospitalized, diagnosed, or exposed. Cases who reside outside of Florida are not counted as Florida cases regardless of whether they became ill or were hospitalized, diagnosed, or exposed in Florida. Cases in out-of-state residents are not included in this report, unless specifically noted. These cases are referred through an interstate reciprocal notification system to the state where the person resides.

6. Population Estimates

All population estimates are from the Community Health Assessment Resource Tool Set (CHARTS), a Florida Department of Health web-based data query system with community tools, health indicators, and data queries for public consumption (www.floridacharts.com/charts/default.aspx). Population estimates within CHARTS are provided by the Florida Department of Health Division of Public Health Statistics and Performance Management, in consultation with the Florida Legislature's Office of Economic and Demographic Research. Estimates in CHARTS are updated at least once per year, and population data were extracted from CHARTS for this report on August 7, 2015. Note that previous editions of this report may show somewhat different populations for a given year than the ones shown here, as these estimates are revised periodically. This is especially true given the recent 2010 census.

7. Florida Disease Codes in Merlin

Reported case data for most reportable diseases (excluding HIV/AIDS, STDs, and tuberculosis) are stored in Merlin, Florida's web-based reportable disease surveillance system. When entering case data into Merlin, users assign a Florida Disease Code based on the disease. Due to changes in case definitions over time, new codes have been added and outdated codes have expired. In addition, some diseases have multiple disease codes that represent different clinical manifestations.

Diseases that include cases from multiple or expired Florida Disease Codes in this report:

- California Serogroup Virus Disease
 California Serogroup Virus Neuroinvasive Disease 06250
 California Serogroup Virus Non-Neuroinvasive Disease 06251
- b. Dengue FeverDengue Fever 06100Dengue Fever, Severe 06101
- c. Eastern Equine Encephalitis
 Eastern Equine Encephalitis Neuroinvasive Disease 06220
 Eastern Equine Encephalitis Non-Neuroinvasive Disease 06221
- d. Ehrlichiosis Ehrlichiosis (*Ehrlichia ewingii*) - 08383 Ehrlichiosis, HME (*Ehrlichia chaffeensis*) - 08382

e. Haemophilus influenzae Invasive Disease in Children <5 Years Old

Haemophilus influenzae Invasive Disease - 03841

Cellulitis (Haemophilus influenzae) - 69290 (EXPIRED)

Epiglottitis (Haemophilus influenzae) - 46430 (EXPIRED)

Meningitis (Haemophilus influenzae) - 32000 (EXPIRED)

Pneumonia (Haemophilus influenzae) - 48220 (EXPIRED)

Septic Arthritis (Haemophilus influenzae) - 71100 (EXPIRED)

f. Hantavirus Infection

Hantavirus Infection, Non-Pulmonary Syndrome - 07870

Hantavirus Pulmonary Syndrome - 07869

g. Listeriosis

Listeriosis - 02700

Meningitis (Listeria monocytogenes) - 32070 (EXPIRED)

h. Plaque

Plague, Bubonic - 02000

Plague, Pneumonic - 02050

i. Poliomvelitis

Poliomyelitis, Nonparalytic - 04520

Poliomyelitis, Paralytic - 04590

- j. Q Fever (Coxiella burnetii)
 - Q Fever, Acute (Coxiella burnetii) 08301
 - Q Fever, Chronic (Coxiella burnetii) 08302
 - Q Fever 08300 (EXPIRED)
- k. Rocky Mountain Spotted Fever and Spotted Fever Rickettsiosis

Rocky Mountain Spotted Fever and Spotted Fever Rickettsiosis - 08309

Rocky Mountain Spotted Fever - 08200 (EXPIRED)

I. Rubella

Rubella - 05690

Rubella, Congenital Syndrome - 77100

m. Shiga Toxin-Producing Escherichia coli Infection

Shiga Toxin-Producing Escherichia coli (STEC) Infection, Non-O157 - 41602 (EXPIRED)

Shiga Toxin-Producing Escherichia coli (STEC) Infection, O157:H7 - 41601 (EXPIRED)

- n. St. Louis Encephalitis
 - St. Louis Encephalitis Neuroinvasive Disease 06230
 - St. Louis Encephalitis Non-Neuroinvasive Disease 06231
- o. Typhus Fever

Typhus Fever, Epidemic (Rickettsia prowazekii) - 08000

Typhus Fever, Endemic (*Rickettsia typhi*) - 08100 (EXPIRED)

Typhus Fever - 08190 (EXPIRED)

p. Venezuelan Equine Encephalitis

Venezuelan Equine Encephalitis Neuroinvasive Disease - 06620

Venezuelan Equine Encephalitis Non-Neuroinvasive Disease - 06621

q. Vibriosis (Excluding Cholera)

Vibriosis (Grimontia hollisae) - 00196

Vibriosis (Vibrio alginolyticus) - 00195

Vibriosis (Vibrio cholerae Type Non-O1) - 00198

Vibriosis (Vibrio fluvialis) - 00194

Vibriosis (Vibrio mimicus) - 00197

Vibriosis (Vibrio parahaemolyticus) - 00540

Vibriosis (Vibrio vulnificus) - 00199

Vibriosis (Other Vibrio Species) - 00193

r. Viral Hemorrhagic Fever

Crimean-Congo Hemorrhagic Fever - 06591

Ebola Hemorrhagic Fever - 06592

Guanarito Hemorrhagic Fever - 06593

Junin Hemorrhagic Fever - 06594

Lassa Fever - 06595

Lujo Virus - 06596

Machupo Hemorrhagic Fever - 06597

Marburg Fever - 06598

Sabia-Associated Hemorrhagic Fever - 06599

Viral Hemorrhagic Fever - 06590 (EXPIRED)

s. West Nile Virus Disease

West Nile Virus Neuroinvasive Disease - 06630

West Nile Virus Non-Neuroinvasive Disease - 06631

t. Western Equine Encephalitis

Western Equine Encephalitis Neuroinvasive Disease - 06210

Western Equine Encephalitis Non-Neuroinvasive Disease - 06211

Summary of Key Disease Trends in 2014

Sexually transmitted diseases (STDs), HIV infection, and AIDS are the most common reportable diseases in Florida, particularly among 20- to 54-year-olds. Chlamydia incidence has been increasing over the past 10 years, with over 84,000 cases reported in Florida in 2014. As chlamydia has increased, the number of gonorrhea cases has consistently decreased nationally and in Florida since 2006. However, in 2013, there was a slight increase in gonorrhea cases compared to 2012. The incidence rate in 2014 was lower than 2013, but still higher than 2012 and slightly higher than the 5-year average incidence rate. The syphilis incidence rate has been increasing since 2009 and increased more in 2014, with a 37.0% increase in 2014 compared to the past five years. The incidence of HIV infection and AIDS has also decreased overall in the last 10 years, though both AIDS and HIV infection increased in 2013, partially due to an expansion of electronic laboratory reporting in 2012 which resulted in receiving more laboratory reports. Incidence of HIV infection increased again in 2014, partially due to a statewide increase in infections in white and Hispanic men who have sex with men, while the incidence of AIDS decreased in 2014.

In the mid-1980s, tuberculosis (TB) re-emerged as a public health threat in the U.S. Since 1994, the number of cases of TB in Florida has decreased every year. The incidence rate in 2014 decreased 22.9% compared to the past five years. Over the past 20 years, the number of TB cases counted in foreign-born people has remained relatively constant while decreasing dramatically in U.S.-born people. Now the proportion of all Florida TB cases that are made up of people born in a foreign country has grown to 62.4% of all TB cases in 2014.

Florida consistently has one of the highest rates of enteric disease in the nation, with 10,000 to 12,000 cases reported annually. Enteric diseases disproportionately affect children less than five years old. Over 13,000 enteric disease cases were reported in 2014, more than any prior year. While salmonellosis was still the largest volume disease with over 6,000 cases, the overall increase in 2014 was primarily due to large increases in cryptosporidiosis and shigellosis. Outbreaks of cryptosporidiosis were identified in swimming pools, a recreational water park, and kiddie pools, and additional community-wide outbreaks were associated with daycares and person-to-person transmission. Historically, shigellosis has a cyclic temporal pattern with large, community-wide outbreaks, frequently involving daycare centers, every three to five years. Shigellosis activity peaked in 2007, 2011, and again in 2014. The incidence of Shiga toxin-producing *E. coli* (STEC) has generally increased since 2006, partially due to widespread implementation of a laboratory screening test that identifies Shiga toxin, prompting additional testing. Though there was a slight decrease in 2014, the incidence rate was still 14.5% higher than the 5-year average.

Despite high vaccine coverage in Florida, vaccine-preventable diseases (VPDs) continue to occur. Vaccination coverage in Florida and nationally for 2014 was published by the Centers for Disease Control and Prevention in the Morbidity and Mortality Weekly Report in August 2014 (see National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19–35 Months — United States, 2014 available at www.cdc.gov/mmwr/preview/mmwrhtml/mm6433a1.htm). In 2014, VPD incidence decreased slightly overall in Florida compared to 2013. Acute hepatitis A and hepatitis B incidence has declined drastically over the past 15 years, largely due to increased vaccination coverage. Though there was a slight increase in hepatitis A in 2013, the incidence rate in 2014 decreased and was 29.0% lower than the previous 5-year average. The acute hepatitis B incidence rate increased 29.0% compared to the previous 5-year average, partially due to an enhanced surveillance project that focuses on chronic hepatitis in young adults. The additional follow-up has resulted in identifying acute cases that would otherwise have been misclassified as chronic. Varicella incidence has been steadily declining since 2008 due to effective vaccination programs. Beginning with the 2008-2009 school year, children entering kindergarten were required to receive two doses of varicella vaccine. Pertussis incidence has increased nationwide over the past 10 years, despite routine vaccine use. In Florida, there was a sharp increase in reported pertussis cases in 2012 and 2013. Incidence decreased slightly in 2014, but was still 43.1% higher than the previous 5-year average.

Tick-borne diseases continued to be a threat in Florida in 2014. Lyme disease, transmitted by ticks, increased in 2014. Consistent with past years, most infections identified in 2014 were acquired in other states (primarily in the Northeast and upper Midwest U.S.). However, while the number of imported cases remained the same in 2014 compared to 2013, there was an increase in the number of reported infections acquired in Florida. Mosquito-borne diseases also continued to occur in Florida in 2014. West Nile virus (WNV) disease incidence decreased dramatically compared to 2012, when a large number of cases were reported in Duval County. The 2012 outbreak likely resulted from many factors, including higher-than-normal temperatures that influenced mosquito and bird abundance, viral replication in host mosquitoes, and interactions of birds and mosquitoes. Dengue fever cases decreased in 2014 and the incidence rate was 26.1% lower than the 5-year average. In 2014, there were five unrelated local introductions in Miami-Dade County, resulting in seven locally acquired dengue fever cases. The first autochthonous transmission of chikungunya virus in the Americas was reported on the island of St. Martin in December 2013. Since then, local transmission was identified in countries throughout the Caribbean and the Americas. Prior to 2014, Florida had five imported cases of chikungunya, all of whom had traveled to Asia. Chikungunya fever became reportable in Florida in June 2014 and over 400 cases were reported.

Starting in March 2014, West Africa experienced the largest outbreak of Ebola virus disease (EVD) in history, with over 28,000 confirmed, probable, and suspect cases identified as of January 2016. In response to the large outbreak, Florida implemented active case finding by conducting in-person twice

-daily temperature monitoring for any traveler returning from Guinea, Liberia, Mali, and Sierra Leone for 21 days. From October 2014 to January 2016, over 760 travelers were monitored in Florida; no EVD cases were identified among these travelers.

Chronic hepatitis C continues to account for a large bulk of infectious disease burden in Florida with over 19,000 confirmed and probable cases reported annually. Over 22,000 cases were reported in 2014, more than any previous year, likely due to improved case ascertainment from electronic laboratory reporting and new automated case classification and reporting logic added to the reportable disease surveillance system, Merlin. Collection of risk factor information has also been improved for chronic hepatitis C cases. In response to an increased rate of chronic hepatitis in young adults, an enhanced surveillance project focusing on chronic hepatitis in young adults was funded and implemented in 2012 in Florida. The additional follow-up has resulted in identifying acute cases that would otherwise have been misclassified as chronic. A large number of new hepatitis C infections in young adults in Florida are due to injection drug use (IDU). In Florida and other states, the dual increases in newly identified hepatitis C infections and IDU among young adults has been associated with the proliferation of highly addictive prescription opioid painkillers.¹

For additional information on disease-specific trends, see Section 1: Summary of Selected Reportable Diseases/Conditions, Section 2: Data Summaries for Selected Reportable Diseases/Conditions of Frequent Occurrence and Section 3: Narratives for Selected Reportable Diseases/Conditions of Infrequent Occurrence.

Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. 2014. Emerging Epidemic of Hepatitis C Virus Infections Among Young Non-Urban Persons who Inject Drugs in the United States, 2006–2012. *Clinical Infectious Diseases*, 59(10):1411-1419.

Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. 2015. Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged ≤30 Years — Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. *Morbidity and Mortality Weekly Report*, 64(17):453-458. Available at www.cdc.gov/mmwr/preview/mmwrhtml/mm6417a2.htm.

List of Reportable Diseases/Conditions in Florida, January 2014

Section 381.0031 (2), Florida Statutes, provides that "Any practitioner licensed in this state to practice medicine, osteopathic medicine, chiropractic medicine, naturopathy, or veterinary medicine; any hospital licensed under part I of Chapter 395, Florida Statutes; or any laboratory licensed under Chapter 483, Florida Statutes that diagnoses or suspects the existence of a disease of public health significance shall immediately report the fact to the Department of Health." Local health offices serve as the Department's representatives in this reporting requirement. Furthermore, section 381.0031 (4), Florida Statutes, provides that "The Department shall periodically issue a list of infectious or noninfectious diseases determined by it to be a threat to public health and therefore of significance to public health and shall furnish a copy of the list to the practitioners . . ." This list of reportable diseases and conditions is maintained in Florida Administrative Code Rule 64D-3.029. The list below reflects diseases and conditions that were reportable in January 2014. The Rule was revised in June 2014; a summary of the changes and the updated list are on the following page.

Any disease outbreak

Any grouping or clustering of disease

Acquired immune deficiency syndrome (AIDS)

Amebic encephalitis

Anthrax

Arsenic poisoning

Botulism

Brucellosis

California serogroup virus disease

Campylobacteriosis

Cancer (excluding non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors)

Carbon monoxide poisoning

Chancroid Chlamydia

Cholera (Vibrio cholerae type O1)

Ciguatera fish poisoning Congenital anomalies

Conjunctivitis in neonates <14 days old Creutzfeldt-Jakob disease (CJD)

Creutzfeldt-Jakob Cryptosporidiosis Cyclosporiasis

Dengue fever Diphtheria

Eastern equine encephalitis Ehrlichiosis/anaplasmosis Encephalitis, other (non-arboviral)

Escherichia coli infection, Shiga toxin-producing

Giardiasis, acute Glanders Gonorrhea

Granuloma inguinale

Haemophilus influenzae invasive disease

Hansen's disease (leprosy) Hantavirus infection

Hemolytic uremic syndrome (HUS)

Hepatitis A

Hepatitis B, C, D, E, and G

Hepatitis B surface antigen in pregnant women or children <2

Herpes simplex virus (HSV) in infants <60 days old with

disseminated infection and liver involvement; encephalitis; and infections limited to skin, eyes, and mouth; anogenital HSV in children <12 years old

Human immunodeficiency virus (HIV) infection

Human papillomavirus (HPV), associated laryngeal papillomas or recurrent respiratory papillomatosis in children <6 years old; anogenital papillomas in children <12 years old

Influenza A, novel or pandemic strains

Influenza-associated pediatric mortality in children <18 years old

Lead poisoning Legionellosis Leptospirosis Listeriosis Lyme disease

Lymphogranuloma venereum (LGV)

Malaria

Measles (rubeola) Melioidosis

Meningitis, bacterial or mycotic Meningococcal disease Mercury poisoning

Mumps

Neurotoxic shellfish poisoning

Pertussis

Pesticide-related illness and injury, acute

Plague Poliomyelitis

Psittacosis (ornithosis)

Q fever

Rabies (human, animal, possible exposure)

Ricin toxin poisoning Rocky Mountain spotted fever

Rubella

St. Louis encephalitis Salmonellosis

Saxitoxin poisoning (paralytic shellfish poisoning)
Severe acute respiratory syndrome (SARS) associated
with coronavirus infection

Shigellosis

Smallpox

Staphylococcal enterotoxin B poisoning

Staphylococcus aureus, intermediate or full resistance

to vancomycin (VISA, VRSA)

Staphylococcus aureus, community-associated mortality

Streptococcal invasive disease (Group A)
Streptococcus pneumoniae invasive disease

Syphilis Tetanus Toxoplasmosis

Trichinellosis (trichinosis)

Tuberculosis Tularemia

Typhoid fever (*Salmonella* serotype Typhi) Typhus fever, epidemic and endemic

Vaccinia disease Varicella (chickenpox)

Venezuelan equine encephalitis Vibriosis (excluding cholera) Viral hemorrhagic fevers

West Nile virus disease

Western equine encephalitis virus disease

Yellow fever

List of Reportable Diseases/Conditions in Florida, June 2014

Florida Administrative Code Rule 64D-3.029 was updated in 2014 to modify the list of reportable diseases and conditions and changes became effective June 4, 2014. Additions and modifications are highlighted below in red. Diseases removed were non-arboviral encephalitis, group A Streptococcal invasive disease, community-associated *Staphylococcus aureus* mortality, endemic typhus fever, and toxoplasmosis. Data in this report reflect the updated list below. Updates may be made to the list of reportable diseases and conditions in future years and these updates will continue to be reflected as appropriate in future *Florida Morbidity Statistics Reports*.

Any disease outbreak

Any grouping or clustering of disease

Acquired immune deficiency syndrome (AIDS)

Amebic encephalitis

Anthrax

Arsenic poisoning

Arboviral diseases not otherwise listed

Botulism

Brucellosis

California serogroup virus disease

Campylobacteriosis

Cancer (excluding non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors)

Carbon monoxide poisoning

Chancroid

Chikungunya fever

Chlamydia

Cholera (Vibrio cholerae type O1)

Ciguatera fish poisoning Congenital anomalies

Conjunctivitis in neonates <14 days old

Creutzfeldt-Jakob disease (CJD)

Cryptosporidiosis

Cyclosporiasis

Dengue fever

Diphtheria

Eastern equine encephalitis

Ehrlichiosis/anaplasmosis

Escherichia coli infection, Shiga toxin-producing

Giardiasis, acute

Glanders

Gonorrhea

Granuloma inguinale

Haemophilus influenzae invasive disease in children <5 years old (all ages for electronic laboratory reporting laboratories)

Hansen's disease (leprosy)

Hantavirus infection

Hemolytic uremic syndrome (HUS)

Hepatitis A

Hepatitis B, C, D, E, and G

Hepatitis B surface antigen in pregnant women or children <2 years

Herpes B virus, possible exposure

Herpes simplex virus (HSV) in infants <60 days old with

disseminated infection and liver involvement; encephalitis; and infections limited to skin, eyes, and mouth; anogenital HSV in children <12 years old

Human immunodeficiency virus (HIV) infection

HIV, exposed infants <18 months old born to an HIV-infected woman Human papillomavirus (HPV), associated laryngeal papillomas or recurrent respiratory papillomatosis in children <6 years old; anogenital papillomas in children <12 years old (all HPV DNA for electronic laboratory reporting laboratories)

Influenza A, novel or pandemic strains

Influenza-associated pediatric mortality in children <18 years old

Lead poisoning

Legionellosis

Leptospirosis

Listeriosis

Lyme disease

Lymphogranuloma venereum (LGV)

Malaria

Measles (rubeola)

Melioidosis

Meningitis, bacterial or mycotic

Meningococcal disease

Mercury poisoning

Mumps

Neonatal abstinence syndrome (NAS)

Neurotoxic shellfish poisoning

Pertussis

Pesticide-related illness and injury, acute

Plague

Poliomyelitis

Psittacosis (ornithosis)

Q Fever

Rabies (human, animal, possible exposure)

Ricin toxin poisoning

Rocky Mountain spotted fever and other spotted fever

rickettsioses

Rubella

St. Louis encephalitis

Salmonellosis

Saxitoxin poisoning (paralytic shellfish poisoning)

Severe acute respiratory disease syndrome associated with coronavirus infection

Shigellosis

Smallpox

Staphylococcal enterotoxin B poisoning

Staphylococcus aureus infection, intermediate or full resistance to vancomycin (VISA, VRSA)

Streptococcus pneumoniae invasive disease in children <6 years old (all ages for electronic laboratory reporting laboratories)

Syphilis

Tetanus

Trichinellosis (trichinosis)

Tuberculosis (TB)

Tularemia

Typhoid fever (Salmonella serotype Typhi)

Typhus fever, epidemic

Vaccinia disease

Varicella (chickenpox)

Venezuelan equine encephalitis

Vibriosis (infections of *Vibrio* species and closely related organisms, excluding *Vibrio* cholerae type O1)

Viral hemorrhagic fevers

West Nile virus disease

Yellow fever

Electronic laboratory reporting laboratories only:

Antimicrobial susceptibility results for isolates from a normally sterile site for *Acinetobacter baumannii*, *Citrobacter* species, *Enterococcus* species, *Enterobacter* species, *Escherichia coli*, *Klebsiella* species, *Pseudomonas aeruginosa*, and *Serratia* species

Hepatitis B, C, D, E, and G viruses, all test results (positive and negative) and all liver function tests

Influenza virus, all test results (positive and negative)

Respiratory syncytial virus, all test results (positive and negative) Staphylococcus aureus isolated from a normally sterile site

ΧV

Florida County Boundaries



Florida Population Estimates¹ by Year, Age Group, Gender, Race, and Ethnicity

Year	Population	Age Group	2014 Population
2005	17,876,663	<1	217,026
2006	18,237,596	1-4	886,618
2007	18,500,958	5-9	1,132,972
2008	18,636,837	10-14	1,146,040
2009	18,711,844	15-19	1,192,611
2010	18,820,278	20-24	1,312,024
2011	18,934,175	25-34	2,448,462
2012	19,042,458	35-44	2,345,727
2013	19,318,859	45-54	2,699,859
2014	19,548,031	55-64	2,574,936
		65-74	1,951,625
		75-84	1,142,703
		85+	497,428
		Total	19,548,031

Gender	2014 Population
Female	9,992,462
Male	9,555,569
Race	2014 Population
White	15,286,521
Black	3,263,817
Other	997,693
Ethnicity	2014 Population
Non-Hispanic	14,861,999
Hispanic	4,686,032
Total	19,548,031

All population estimates are from the Community Health Assessment Resource Tool Set (CHARTS), a Florida Department of Health web-based data query system with community tools, health indicators, and data queries for public consumption (www.floridacharts.com/charts/default.aspx). Population estimates within CHARTS are provided by the Florida Department of Health Division of Public Health Statistics and Performance Management, in consultation with the Florida Legislature's Office of Economic and Demographic Research. Estimates in CHARTS are updated at least once per year, and population data were extracted from CHARTS for this report on August 7, 2015. Note that previous editions of this report may show somewhat different populations for a given year than the ones shown here, as these estimates are revised periodically. This is especially true given the recent 2010 census.

Florida Morbidity Statistics Report Editors and Contributors

Editors	
Leah Eisenstein, MPH (Lead Editor)	.Bureau of Epidemiology
Jamie DeMent, MNS (Section Editor)	.Bureau of Epidemiology
Ellen Dugan, MPH (Section Editor)	.Bureau of Epidemiology
Scott Pritchard, MPH (Section Editor)	.Bureau of Epidemiology
Heather Rubino, PhD, MS (Section Editor)	.Bureau of Epidemiology
Danielle Stanek, DVM (Section Editor)	.Bureau of Epidemiology
Jon Teter (Section Editor)	.Bureau of Epidemiology
Janet Hamilton, MPH (Senior Editor)	.Bureau of Epidemiology
Michael Wydotis (Reviewer)	.Bureau of Epidemiology
Chad Bailey (Reviewer)	.Bureau of Epidemiology
German Gonzalez, MD, MPH	.Bureau of Epidemiology
Russell Eggert, MD, MPH, FACPM, FAAFP	.Bureau of Epidemiology, Chief
Carina Blackmore, DVM, PhD, Dipl ACVPM	Division of Disease Control and Health Protection Bureau of Public Health Laboratories, Chief Deputy State Epidemiologist
Anna Likos, MD, MPH	Division of Disease Control and Health Protection State Epidemiologist

Florida Department of Health (DOH) Contributors

(
Rebecca Alcantara, RN, BSN	DOH-Duval	
Deborah Andrews, LPN	DOH-Orange	
Anne Barrera, MPH	DOH-Miami-Dade	
Kat Beedie, BS, CEHP	DOH-Okaloosa	
Andrea Bingham, PhD, MSPH	Bureau of Epidemiology	
Dean Bodager, RS, MPA	Bureau of Epidemiology	
Rene Borroto-Ponce, MPH	DOH-Miami-Dade	
Erika Cathey, MPH	Bureau of Epidemiology	
Philip Cavicchia, PhD	Bureau of Epidemiology	
Karen Chapman, MD, MPH	DOH-Okaloosa	
Ulyee Choe, DO	DOH-Polk	
Charles Clark, MPH	Bureau of Epidemiology	
Pam Colarusso, MSH	Bureau of Public Health Laboratories	
Maura Comer, MPH, CPH	Bureau of Communicable Diseases, STDs and Viral Hepatitis Section	
Marshall Cone, MPH, CPH, MT(AAB)	Bureau of Public Health Laboratories	
Diana Connor, MPH	DOH-Palm Beach	
Karen Coombs, BSN	DOH-Orange	
Terry Cooper	DOH-Alachua	
Jenny Crain, MS, MPH, CPH	Bureau of Epidemiology	
Ken Danielson	DOH-Lee	

Greg Danyluk, PhD, MPH, MS	DOH-Polk	
David Dekevich, MPH	Bureau of Epidemiology	
Stephanie Forhan, MPH	DOH-Broward	
Mike Friedman, MPH	Bureau of Epidemiology	
Maritza Godwin, BSN, MPH	DOH-Orange	
Eliot Gregos, MPH, RS	DOH-Hillsborough	
Dana Grissom, BS, CEHP	DOH-Okaloosa	
Megan Gumke, MPH	Bureau of Epidemiology	
Carrie Harter, MPH	DOH-Manatee	
Lea Heberlein-Larson, MPH, SM(ASCP)CM	Bureau of Public Health Laboratories	
lan Henning, DM	Bureau of Communicable Diseases, STDs and Viral Hepatitis Section	
Toni Hudson, MSPH	Bureau of Epidemiology	
Shaiasia Itwaru-Womack, MPH	Bureau of Epidemiology	
Reynald Jean, MD, MPH, MSN, AGPCNP-BC	DOH-Miami-Dade	
Patrick Jenkins, MPH	DOH-Broward	
Lori Johnston	Bureau of Communicable Diseases, Tuberculosis Control Section	
John Jordan, MD, MPH	Bureau of Epidemiology	
Deborah Kahn, RN	Bureau of Communicable Diseases, Immunization Section	
Ken Kampert, MS, MPH	Bureau of Communicable Diseases, STDs and Viral Hepatitis Section	
Cynthia Keeton	DOH-Hillsborough	
Katie Kendrick, MPH	Bureau of Epidemiology	
Nicole Kikuchi, MPH	Bureau of Epidemiology	
Ruth Kim, MPH, MD	DOH-St. Lucie	
Diane King, MSPH, RN	DOH-Palm Beach	
Benjamin Klekamp, MSPH, CPH	DOH-Orange	
Kim Kossler, MPH, RN, CPH	DOH-St. Lucie	
Nadia Kovacevich, MPH, CPH	DOH-Alachua	
JoAnne Lamb, MPH	DOH-Pinellas	
Andrea Leapley, MPH	DOH-Pinellas	
Shamilla Lutchman	DOH-Palm Beach	
Tammy Lynn, RN	DOH-St. Lucie	
Lorene Maddox, MPH	Bureau of Communicable Diseases,	
	HIV/AIDS Section	
Erin Mahler		
Erin MahlerMichelle Mancilla, BSN	Bureau of Epidemiology	
	Bureau of Epidemiology DOH-Orange	
Michelle Mancilla, BSN	Bureau of Epidemiology DOH-Orange DOH-Orange	

	STDs and Viral Hepatitis Section	
Laura Matthias, MPH	Bureau of Epidemiology	
Tim Mayer, RS, MPH	DOH-Palm Beach	
Warren McDougle, MPH	DOH-Hillsborough	
Leslie McKay, MPH, CPH	DOH-Polk	
Alvaro Mejia-Echeverry, MD, MPH	DOH-Miami-Dade	
Amira Mithavayani, MPH	DOH-Broward	
Valerie Mock, MPH, MT(ASCP)	Bureau of Public Health Laboratories	
Madgene Moise, MPH	Bureau of Communicable Diseases, HIV/AIDS Section	
Angela Morgan, RN, BSN	DOH-Duval	
Prakash Mulay, MBBS, MPH	Bureau of Epidemiology	
Bonnie Mull, MPH	Bureau of Epidemiology	
Julia Munroe, MS	Bureau of Epidemiology	
Garik Nicholson, MPH	DOH-Pasco	
Pedro Noya-Chaveco, MD, MPH	DOH-Miami-Dade	
Robert Parkes, MD, MPH	DOH-Palm Beach	
Amanda Pullman, MT(AAB)	DOH-Hillsborough	
Sudha Rajagopalan, MPH	Bureau of Epidemiology	
Ashley Rendon	DOH-Okaloosa	
Edhelene Rico, MPH	DOH-Miami-Dade	
Jennifer Roth, MSPH	DOH-Lee	
Heather Rubino, PhD	Bureau of Epidemiology	
Lylah Seaton, MPH, MT(ASCP)	Bureau of Public Health Laboratories	
Valerie Shipley, RN, BSN	Bureau of Communicable Diseases, Immunization Section	
Tania Slade, MPH	DOH-Seminole	
Robin Terzagian	Bureau of Epidemiology	
Makenzie Tewell, MA, MPH, CPH	DOH-Hillsborough	
Lori Theisen, BSN	DOH-Orange	
Karen Thomas, MD, MPH	DOH-Palm Beach	
Dearline Thomas-Brown, MPH, RN, BSN	Bureau of Communicable Diseases, Immunization Section	
Antonio Tovar-Aguilar, PhD	Bureau of Epidemiology	
Jack Tracy, Med	DOH-Orange	
Ruth Voss, MPH, RN	DOH-Duval	
Sharon Watkins, PhD	Bureau of Epidemiology	
Mike Wiese, MPH, CPH	DOH-Hillsborough	
Tiffany Winston, MPH	Bureau of Epidemiology	

Selected Division of Disease Control and Health Protection Contacts

Bureau of Epidemiology (850) 245-4401 (accessible 24 hours a day, 7 days a week, 365 days a year)

Bureau of Communicable Diseases

HIV/AIDS Section (850) 245-4334

Immunization Section (850) 245-4342

Sexually Transmitted Diseases and Viral Hepatitis Section (850) 245-4303

Tuberculosis Control Section (850) 245-4350